Press Releases

We lead the synthetic biology industry, having developed and successfully commercialized the most Lab-to-Market™ ingredients. Our sustainable ingredients are used in thousands of top global brands, including our own family of consumer brands in Clean Beauty and Health markets.

AMYRIS, INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
  • Sixth consecutive quarter of record consumer revenue – Consumer revenue of $46.6 million increased 98% compared to Q3 2021
  • Record core revenue of $71.1 million grew 49% compared to the prior year quarter
  • "Fit to Win" revenue, cost and cash actions deliver $10 million in Q3
  • $180 million of new funding closed - strategic transaction on track to self-fund growth

EMERYVILLE, Calif., Nov. 8, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced financial results for the third quarter ended September 30, 2022.

"Q3 2022 core revenue of $71.1 million grew 49% versus Q3 2021 driven by record consumer revenue of $46.6 million, a 98% year-over-year increase for the quarter and 107% consumer revenue growth year-to-date. Amyris outperformed key players in the beauty space according to the NielsenIQ 12 weeks trailing year-over-year growth rate of 7%," commented John Melo, President and Chief Executive Officer. "Our ingredient business continued to sell out all production and entered the fourth quarter with an order backlog."

Industry-wide prestige and luxury consumers continued to show resilience in the face of a slowing global economy as did key beauty categories such as clean beauty where Amyris has leading consumer brands. Amyris entered the emerging menopausal category through its MenoLabs™ acquisition and recent launch of Stripes™. The company's omnichannel strategy continues to deliver strong growth with direct-to-consumer ecommerce representing 45% of Q3 consumer revenue. Consumer products were in nearly 14,000 stores compared to 2,100 in the year ago quarter, and Amyris continued its international expansion, particularly into the U.K. and European markets.

"We have built the leading Lab-to-Market™ technology platform for synthetic biology and bio-manufacturing. After an extended period of rapid organic growth and acquisition activity, we are increasingly focused on brand integration, cash conversion efficiency, and cost optimization to achieve our profitability goals," commented Mr. Melo. "To reach these goals, we completed previously announced fundraising of $80 million in Q3 and $100 million in Q4. Additionally, we are on track to complete a substantial strategic transaction by year end."

During the third quarter, Amyris embarked on companywide "Fit to Win" initiatives intended to reduce the use of cash and improve the company's cost structure. These resulted in approximately $10 million in earnings improvement in Q3. The benefits of these initiatives are accelerating in the fourth quarter and are expected to have a favorable annualized impact of $150 million in 2023.

"We have the scale, growth rate and business model that enables us to evolve our focus to operating profitability. Our current growth momentum has continued into the fourth quarter, and we are tracking toward our first quarter of more than $100 million in core revenue while controlling our costs and improving our use of cash," concluded Melo.

Revenue

Core revenue comprises consumer and technology access revenue. Technology access includes ingredient product revenue, R&D collaboration, and technology licenses. Core revenue excludes strategic transactions and other. Totals may not foot due to rounding.


Three Months
 Ended Sept 30,


Nine Months
Ended Sept 30,

(In millions)

2022

2021

YoY%


2022

2021

YoY%

  Consumer

$  46.6

$  23.5

98 %


124.1

59.8

107 %

  Technology Access

24.6

24.4

1 %


70.0

63.4

10 %









Core

71.1

47.9

49 %


194.0

123.2

57 %

  Strategic Transactions & Other1

0.0

0.0

-


0.0

153.8

-100 %









Reported Total

$  71.1

$  47.9

49 %


194.0

277.0

-30 %









1Strategic Transactions & Other includes $143.6 million Flavors & Fragrances transaction (Q1 2021); $0.2 million discontinued ingredients value share (Q1 2021); and $10.0 million RebM transaction (Q2 2021)

Q3 2022 Financial Highlights

  • Core revenue of $71.1 million increased 49% compared to Q3 2021 revenue of $47.9 million. Q3 2022 core revenue included record consumer revenue of $46.6 million, an increase of $23.1 million or 98%.
  • Consumer revenue growth was primarily due to the growth of Biossance®, JVN™, MenoLabs and Rose Inc.™, however, all brands within the Company's clean beauty consumer portfolio demonstrated an above market increase in revenue year-over-year. Direct-to-consumer sales, which comprised 45% of total consumer sales, grew 93% compared to Q3 2021. Retail sales through third party channels, which comprised 55% of total consumer sales, grew 97% compared to Q3 2021. Amyris brands were available in nearly 14,000 physical locations compared to 2,100 during the same quarter last year.
  • Increased technology license revenue was offset by lower R&D collaboration revenue. Ingredients product revenue increased 2%, to $13.5 million, as the newly commissioned biomanufacturing plant in Barra Bonita began to ease pre-existing third-party capacity constraints.
  • Non-GAAP gross margin of $28.5 million, or 40% of revenue, increased from $17.7 million, or 37% of revenue in Q3 2021. Q3 2022 gross margin reflects a year-over-year increase in consumer revenue and technology license revenue, partially offset by lower R&D collaboration and higher ingredients input costs.
  • Non-GAAP cash operating expense of $137.8 million was sequentially flat and increased by $56.4 million compared to Q3 2021 due to an increase of $42.1 million in selling expense, $9.7 million in G&A expense, and $4.6 million in R&D expense. The increases were primarily driven by a combination of increased headcount (both organic and from acquisitions) and investments in existing and developing consumer brands.
  • Adjusted EBITDA of -$131.7 million decreased $59.3 million, primarily due to higher operating expense and freight costs.
  • GAAP net loss was influenced by $14.4 million of unfavorable non-cash mark-to-market adjustments related to changes in the fair value of debt and derivatives. GAAP net loss of $161.4 million, or a loss of $0.50 per diluted share, compared to a net loss of $32.9 million, or $0.27 per diluted share, in Q3 2021.
  • Cash at the end of Q3 2022 was $24.6 million, compared to $106.5 million at the end of Q2 2022.

YTD Q3 2022 Financial Highlights

  • Core revenue of $194.0 million increased 57% compared to $123.2 million in the first nine months of 2021. YTD 2022 core revenue included record consumer revenue of $124.1 million, an increase of 107% compared to 2021, and technology access revenue of $70.0 million, an increase of 10% compared to the same period in 2021. Total revenue of $194.0 million decreased 30% compared to the prior year period which included $153.8 million licensing revenue from strategic transactions.
  • Non-GAAP core gross margin of $83.7 million, or 43% of revenue, excluding the $153.8 million from the 2021 strategic transactions, increased from $51.2 million or 42% of revenue.
  • Non-GAAP cash operating expense of $391.6 million increased by $193.6 million, compared to the first nine months of 2021 primarily due to an increase of $145.0 million in selling expense, $38.0 million in G&A expense, and $10.7 million in R&D expense. The increases were primarily driven by a combination of increased headcount (both organic and from acquisitions) and investments in existing and developing consumer brands such as paid media and fulfillment and shipping.
  • Adjusted EBITDA of -$364.2 million decreased $199.5 million, excluding $153.8 million from the 2021 strategic transactions, primarily due to higher ingredients COGS, and higher operating expense.
  • GAAP net loss was influenced by $46.9 million of favorable non-cash mark-to-market adjustments related to changes in the fair value of debt and derivatives. GAAP net loss was $378.7 million, or a loss of $1.24 per diluted share, compared to a loss of $308.0 million, or a loss of $1.07 per diluted share, through the first 9 months of 2021.

Q4 and Full Year 2022 Updated Financial Outlook

Consumer revenue is expected to continue growing at the current rate. Ingredients revenue is accelerating supported by increased Barra Bonita production output and shipments in the fourth quarter. As a result, Q4 2022 core revenue is expected to be more than $100 million.

We are evolving to balancing profitability and use of cash with revenue growth. We expect to continue delivering the leading revenue growth among our peers in consumer health, beauty, and wellness end-markets along with continuing as the leader in biomanufacturing and clean, sustainable ingredients supply.

Conference Call

Amyris will host a conference call today at 4:30 pm ET (1:30 pm PT) to discuss its Q3 2022 financial results and provide a business and financial update.

Live audio webcast/conference call:

Webcast: please visit http://investors.amyris.com.
U.S. Dial-In Number: (844) 850-0551. International Dial-In Number: (412) 902-4203.

Please connect to the website or dial in to the conference call 15 minutes prior to the start of the call to avoid connection delays. If a participant will be listen-only, they are encouraged to listen via the webcast on Amyris' investor page.

A replay of the webcast will be available on the Investor Relations section of Amyris' website.

FINANCIAL RESULTS AND NON-GAAP INFORMATION

To supplement our financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures that we believe are helpful in understanding our financial results. These non-GAAP financial measures are among the factors management uses in planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to Amyris' historical performance as well as comparisons to the operating results of other companies. Management believes these non-GAAP financial measures, when considered together with financial information prepared in accordance with GAAP, can enhance investors' and analysts' abilities to meaningfully compare our results from period to period, identify operating trends in our business, and track and model our financial performance. In addition, our management believes that these non-GAAP financial measures allow for greater transparency into the indicators used by management to understand and evaluate our business and make operating decisions.

Non-GAAP financial information is not prepared under a comprehensive set of accounting rules, and therefore, should only be read in conjunction with financial information reported under GAAP in order to understand Amyris' operating performance. A reconciliation of the non-GAAP financial measures presented in this release to the most directly comparable GAAP financial measure, is provided in the tables attached to this press release.

Our Non-GAAP financial measures include the following:

Non-GAAP Gross Margin (Gross Margin) is calculated as GAAP revenue less non-GAAP cost of products sold. Non-GAAP cost of products sold excludes other costs/provisions, inventory lower of cost or net realizable value adjustments, excess capacity, manufacturing capacity fee adjustments, stock-based compensation expense, depreciation and amortization

Non-GAAP Cash Operating Expense is calculated as GAAP Operating Expense minus non-cash stock-based compensation, depreciation and amortization, non-recurring transaction and acquisition expense, contract credit loss reserve, and R&D performance agreement termination.

EBITDA is calculated as GAAP net income (loss) less interest, expense, income tax expense, depreciation and amortization expense, and loss allocated to participating securities.

Adjusted EBITDA is calculated as EBITDA less income attributable to noncontrolling interest, gain/loss from change in fair value of derivatives, gain/loss from changes in the fair value of debt, loss upon debt extinguishment, other income/expense, loss from investment in affiliate, inventory lower of cost or net realizable value adjustments, non-recurring transaction and acquisition expense, stock-based compensation expense, R&D performance agreement termination, manufacturing capacity fee adjustment and contract asset credit loss reserve.

Adjusted net income (loss) is calculated as GAAP net income/loss excluding stock-based compensation expense, gain/loss from change in fair value of derivatives, gain/ loss from changes in the fair value of debt, losses upon debt extinguishment, income/loss attributable to noncontrolling interest, loss allocated to participating securities, inventory lower of cost or net realizable value adjustments, R&D performance agreement termination, manufacturing capacity fee adjustments, non-recurring transaction and acquisition expense, other income/expense, and gain/loss from investment in affiliate.

Adjusted EPS is calculated by dividing adjusted net income (loss) by the weighted average shares, basic outstanding for the period.

About Amyris

Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the company's proprietary Lab-to-Market™ technology platform. This Amyris platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective and accessible products. For more information, please visit http://www.amyris.com

Amyris, the Amyris logo, Biossance, JVN, Lab-to-Market, MenoLabs, Rose Inc. and Stripes are trademarks or registered trademarks of Amyris, Inc. or its subsidiaries in the U.S. and/or other countries.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as Amyris' financial outlook for the remainder of 2022 including Q4 core revenue; Amyris' 2022 goals, including a potential strategic transaction to self-fund growth and the timing thereof, and initiatives to improve brand integration, cash conversion efficiency and cost optimization to achieve profitability goals; and Amyris' expectations regarding the impact of "Fit to Win" initiatives on Q4 2022 and 2023 financial results. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris' liquidity and ability to fund operating and capital expenses, risks related to its financing activities, risks related to potential delays or failures in completing and integrating planned acquisitions, risks related to potential delays or failures in development, regulatory approval, launch, production and commercialization of products, risks related to global inflation and policy measures undertaken to address inflation, the COVID-19 pandemic and any other geopolitical events, including Russia's invasion of Ukraine, resulting in global economic, financial and supply chain disruptions that may negatively impact Amyris' business operations and financial results or cause market volatility, risks related to Amyris' reliance on third parties particularly in the supply chain, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

Financial Tables Follow

 

Amyris, Inc. 




CONDENSED CONSOLIDATED BALANCE SHEETS




(In thousands

September 30, 2022

December 31, 2021


Assets




Current assets:




Cash and cash equivalents

$                       18,489

$                    483,462


Restricted cash

93

199


Accounts receivable, net

40,410

37,074


Accounts receivable - related party, net

7,428

5,667


Contract assets

3,361

4,227


Contract assets - related party

25,371

-


Inventories

129,332

75,070


Prepaid expenses and other current assets

47,998

33,513


Total current assets

272,482

639,212


Property, plant and equipment, net

169,827

72,835


Restricted cash, noncurrent

6,057

4,651


Recoverable taxes from Brazilian government entities

22,382

16,740


Right-of-use assets under financing leases, net

329

7,342


Right-of-use assets under operating leases, net

88,459

32,428


Goodwill

126,660

131,259


Intangible assets, net

54,662

39,265


Other assets

13,202

10,566


Total assets

$                     754,060

$                    954,298


Liabilities, Mezzanine Equity and Stockholders' Deficit




Current liabilities:




Accounts payable

$                     133,819

$                      79,666


Accrued and other current liabilities

84,541

71,457


Financing lease liabilities

12

140


Operating lease liabilities

1,589

7,689


Contract liabilities

953

2,530


Debt, current portion

1,720

896


Related party debt, current portion

86,628

107,427


Total current liabilities

309,262

269,805


Long-term debt, net of current portion

673,927

309,061


Related party debt, net of current portion

51,570

-


Financing lease liabilities, net of current portion

51

61


Operating lease liabilities, net of current portion

75,898

19,829


Derivative liabilities

3,303

7,062


Acquisition-related contingent consideration

40,275

64,762


Other noncurrent liabilities

4,578

4,510


Total liabilities

1,158,864

675,090


Commitments and contingencies




Mezzanine equity:




Contingently redeemable common stock

5,000

5,000


Redeemable noncontrolling interest

30,882

28,520


Stockholders' (deficit) equity:




Common stock

32

31


Additional paid-in capital

2,384,348

2,656,838


Accumulated other comprehensive loss

(81,582)

(52,769)


Accumulated deficit

(2,730,381)

(2,357,661)


Total Amyris, Inc. stockholders' (deficit) equity

(427,583)

246,439


Noncontrolling interest

(13,103)

(751)


Total stockholders' (deficit) equity

(440,686)

245,688


Total liabilities, mezzanine equity and stockholders' (deficit) equity

$                     754,060

$                    954,298


 

Amyris, Inc. 






CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)







Three Months Ended September 30,


Nine Months Ended September 30,

(In thousands, except shares and per share amounts)

2022

2021


2022

2021

Revenue:






Renewable products

$          58,563

$          36,508


$        156,418

$        101,859

Licenses and royalties

10,113

6,006


25,880

160,806

Collaborations, grants and other

2,453

5,352


11,747

14,376

Total revenue

71,129

47,866


194,045

277,041

Cost and operating expenses:






Cost of products sold(1)

65,818

40,252


170,743

93,332

Research and development(1)

28,780

23,824


81,249

69,580

Sales, general and administrative(1)

124,709

70,635


358,212

162,897

Impairment

-

-


-

-

Total cost and operating expenses

219,307

134,711


610,204

325,809

Loss from operations

(148,178)

(86,845)


(416,159)

(48,768)

Other income (expense):






Interest expense

(6,289)

(4,321)


(16,856)

(14,857)

Gain (loss) from change in fair value of derivative instruments

(1,654)

4,778


3,759

(12,826)

Gain (loss) from change in fair value of debt

(12,689)

52,294


43,221

(204,359)

Gain (loss) upon extinguishment of debt

-

(680)


-

(27,058)

Other income (expense), net

1,688

690


(584)

40

Total other income (expense), net

(18,944)

52,761


29,540

(259,060)

Loss before income taxes and loss from investment in affiliate

(167,122)

(34,084)


(386,619)

(307,828)

Benefit from (provision for) income taxes

(152)

(58)


1,353

(170)

(Loss) gain from investment in affiliate

(748)

181


(6,509)

(567)

Net loss

(168,022)

(33,961)


(391,775)

(308,565)

Less: loss (income) attributable to noncontrolling interest

6,627

1,017


13,062

(249)

Net loss attributable to Amyris, Inc.

(161,395)

(32,944)


(378,713)

(308,814)

Less: (income) loss allocated to participating securities

-

-


-

787

Net loss attributable to Amyris, Inc. common stockholders

$      (161,395)

$        (32,944)


$      (378,713)

$      (308,027)







Weighted-average shares of common stock outstanding used in computing loss per share of
common stock, basic

322,286,529

300,888,579


318,400,804

286,919,463

Loss per share attributable to common stockholders, basic

$            (0.50)

$            (0.11)


$            (1.19)

$            (1.07)







Weighted-average shares of common stock outstanding used in computing loss per share of
common stock, diluted

322,286,529

317,568,913


335,126,922

286,919,463

Loss per share attributable to common stockholders, diluted

$            (0.50)

$            (0.27)


$            (1.24)

$            (1.07)







(1) Includes stock-based compensation expense as follows:






Cost of products sold

$                 79

$                 79


$               238

$               216

Research and development 

1,607

1,565


5,007

3,945

Sales, general and administrative

10,624

7,261


31,299

17,772


$          12,310

$            8,905


$          36,544

$          21,933







Amyris, Inc. 






RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(Unaudited)







Three Months Ended September 30,


Nine Months Ended September 30,

(In thousands, except per share data)

2022

2021


2022

2021

Net loss attributable to Amyris, Inc. common stockholders - Basic (GAAP)

$      (161,395)

$        (32,944)


$      (378,713)

$      (308,027)

Non-GAAP adjustments:






Loss allocated to participating securities

-

-


-

(787)

M&A transaction legal expense

94

2,216


2,153

5,522

Manufacturing capacity fee adjustment

340

-


2,956

1,482

Inventory lower-of-cost-or-net realizable value adjustment

(655)

50


(1,010)

(1,183)

R&D Performance Agreement termination

-

-


-

1,850

Hand sanitizer write-off

-

734


(94)

1,250

Stock-based compensation expense

12,310

8,905


36,544

21,933

(Gain) loss from change in fair value of derivative instruments

1,654

(4,778)


(3,759)

12,826

(Gain) loss from change in fair value of debt

12,689

(52,294)


(43,221)

204,359

Loss upon extinguishment of debt

-

680


-

27,058

Income (loss) attributable to noncontrolling interest

(6,627)

(1,017)


(13,062)

249

Other expense, net, and loss (gain) from investment in affiliate, net

(940)

(871)


7,093

527

Net loss attributable to Amyris, Inc. common stockholders (non-GAAP)

$      (142,530)

$        (79,319)


$      (391,113)

$        (32,941)







Weighted-average shares outstanding






Weighted-average shares of common stock outstanding used in computing loss per share
attributable to Amyris, Inc. common stockholders, basic (GAAP and non-GAAP)

322,286,529

300,888,579


318,400,804

286,919,463







Loss per share attributable to Amyris, Inc. common stockholders - Basic (GAAP)

$            (0.50)

$            (0.11)


$            (1.19)

$            (1.07)

Non-GAAP adjustments:






Loss allocated to participating securities

-

-


-

(0.00)

M&A transaction legal expense

0.00

0.01


0.01

0.02

Manufacturing capacity fee adjustment

0.00

-


0.01

0.01

Inventory lower-of-cost-or-net realizable value adjustment

(0.00)

0.00


(0.00)

(0.00)

R&D Performance Agreement termination

-

-


-

0.01

Hand sanitizer write-off

-

0.00


(0.00)

0.00

Stock-based compensation expense

0.04

0.03


0.11

0.08

(Gain) loss from change in fair value of derivative instruments

0.01

(0.02)


(0.01)

0.04

(Gain) loss from change in fair value of debt

0.04

(0.17)


(0.14)

0.71

Loss upon extinguishment of debt

-

0.00


-

0.09

Income (loss) attributable to noncontrolling interest

(0.02)

(0.00)


(0.04)

0.00

Other expense, net, and loss (gain) from investment in affiliate, net

(0.00)

(0.00)


0.02

0.00

Loss per share attributable to Amyris, Inc. common stockholders (non-GAAP)(1)

$            (0.44)

$            (0.26)


$            (1.23)

$            (0.11)

(1) Amounts may not sum due to rounding.

-

-


-

-


Three Months Ended September 30,


Nine Months Ended September 30,

ADJUSTED EBITDA

2022

2021


2022

2021

GAAP net loss attributable to Amyris, Inc. common stockholders - Basic

$      (161,395)

$        (32,944)


$      (378,713)

$      (308,027)

Interest expense

6,289

4,321


16,856

14,857

Income taxes

152

58


(1,353)

170

Depreciation and amortization

4,376

2,571


11,437

7,007

Loss allocated to participating securities

-

-


-

(787)

EBITDA

(150,578)

(25,994)


(351,773)

(286,780)

Manufacturing capacity fee adjustment

340

-


2,956

1,482

Inventory lower-of-cost-or-net realizable value adjustment

(655)

50


(1,010)

(1,183)

Hand sanitizer write-off

-

734


(94)

1,250

R&D Performance Agreement termination

-

-


-

1,850

M&A transaction legal expense

94

2,216


2,153

5,522

Stock-based compensation expense

12,310

8,905


36,544

21,933

(Gain) loss from change in fair value of derivative instruments and debt, (gain) loss upon
extinguishment of debt, other (income) expense, and (gain) loss from investment in affiliate

13,403

(57,263)


(39,887)

244,770

(Loss) income attributable to noncontrolling interest

(6,627)

(1,017)


(13,062)

249

Adjusted EBITDA

$      (131,713)

$        (72,369)


$      (364,173)

$        (10,907)

 

Amyris, Inc. 






RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(Unaudited)







Three Months Ended September 30,


Nine Months Ended September 30,

(In thousands)

2022

2021


2022

2021

Revenue (GAAP and non-GAAP)






Renewable products

$    58,563

$  36,508


$  156,418

$  101,859

Licenses and royalties

10,113

6,006


25,880

160,806

Collaborations, grants and other

2,453

5,352


11,747

14,376

Revenue (GAAP and non-GAAP)

$    71,129

$  47,866


$  194,045

$  277,041







Cost of products sold (GAAP)

$    65,818

$  40,252


$  170,743

$    93,332

Other costs and provisions

(21,738)

(7,956)


(54,199)

(16,121)

Manufacturing capacity fee adjustment

(340)

-


(2,956)

(1,482)

Hand sanitizer write-off

-

(734)


94

(1,250)

Excess capacity

(696)

(762)


(2,107)

(1,799)

Inventory lower-of-cost-or-net realizable value adjustment

655

(50)


1,010

1,183

Stock-based compensation expense

(79)

(79)


(238)

(216)

Depreciation and amortization

(1,014)

(554)


(2,030)

(1,618)

Cost of products sold (non-GAAP)

$    42,606

$  30,117


$  110,317

$    72,029







Adjusted gross margin (non-GAAP)

$    28,523

$  17,749


$    83,728

$  205,012

Gross margin %

40 %

37 %


43 %

74 %







Research and development expense (GAAP)

$    28,780

$  23,824


$    81,249

$    69,580

Stock-based compensation expense

(1,607)

(1,565)


(5,007)

(3,945)

Depreciation and amortization

(1,663)

(1,366)


(4,756)

(4,037)

R&D performance agreement termination

-

-


-

(1,850)

Research and development expense (non-GAAP)

$    25,510

$  20,893


$    71,486

$    59,748







Sales, general and administrative expense (GAAP)

$  124,709

$  70,635


$  358,212

$  162,897

Stock-based compensation expense

(10,624)

(7,261)


(31,299)

(17,772)

Depreciation and amortization

(1,699)

(651)


(4,651)

(1,352)

M&A transaction legal expense

(94)

(2,216)


(2,153)

(5,522)

Sales, general and administrative expense (non-GAAP)

$  112,292

$  60,507


$  320,109

$  138,251







Cash operating expense

$  137,802

$  81,400


$  391,595

$  197,999

 

 

SOURCE Amyris, Inc.

For further information: Investors: Amyris, Inc., Paul Vincent, vincent@amyris.com, +1 (510) 450-0761; Argot Partners, Jason Finkelstein, amyris@argotpartners.com, +1 (212) 600-1902; Media: Amyris, Inc., Beth Bannerman, bannerman@amyris.com, +1 (510) 914-0022
Contact Us

Beth Bannerman
Chief Engagement & Sustainability Officer
Amyris, Inc. 
pr@amyris.com